Skip to main content

Table 1 Summary of protein kinase inhibitors suppressing mammosphere formation

From: Screening of breast cancer stem cell inhibitors using a protein kinase inhibitor library

Number

Name

Targets

Inhibitory activity

Number

Name

Targets

Inhibitory activity

B1

PD-98059

MEK

Negative

C1

Tyrphostin 46

EGFRK, PDGFRK

Negative

B2

U-0126

MEK

Negative

C2

Tyrphostin 47

EGFRK

Negative

B3

SB-203580

p38 MAPK

Negative

C3

Tyrphostin 51

EGFRK

Negative

B4

H-7 2HCl

PKA, PKG, MLCK, PKC

Negative

C4

Tyrphostin 1

Negative control for tyrosine kinase

Negative

B5

H-9 HCl

PKA, PKG, MLCK, PKC

Negative

C5

Tyrphostin AG 1288

Tyrosine kinases

Negative

B6

Staurosporine

Pan-specific

Negative

C6

Tyrphostin AG 1478

EGFRK

Positive

B7

AG-494

EGFRK, PDGFRK

Negative

C7

Tyrphostin AG1295

Tyrosine kinases

Negative

B8

AG-825

HER1-2

Negative

C8

Tyrphostin 9

PDGFRK

Negative

B9

Lavendustin A

EGFRK

Negative

C9

Hydroxy-2-naphthalenyl methylphosphonic acid

IRK

Negative

B10

RG-1462

EGFRK

Negative

C10

PKC-412

PKC inhibitor

Negative

B11

Tyrphostin 23

EGFRK

Negative

C11

Piceatannol

Syk

negative

B12

Tyrphostin 25

EGFRK

Negative

C12

PP1

Src family

Negative

D1

AG-490

JAK-2

Negative

E1

HA-1004 2HCl

PKA, PKG

Negative

D2

AG-126

IRAK

Negative

E2

HA-1077 2HCl

PKA, PKG

Negative

D3

AG-370

PDGFRK

Negative

E3

2-Hydroxy-5-(2,5-dihydroxy benzyl amino) benzoic acid

EGFRK, CaMK II

Negative

D4

AG-879

NGFRK

Negative

E4

KN-62

CaMK II

Positive

D5

LY 294002

PI 3-K

Negative

E5

KN-93

CaMK II

Positive

D6

Wortmannin

PI 3-K

Negative

E6

ML-7 HCl

MLCK

Positive

D7

GF 109203X

PKC

Negative

E7

ML-9 HCl

MLCK

Negative

D8

Hypericin

PKC

Negative

E8

2-Aminopurine

p58 PITSLRE beta1

Negative

D9

Ro 31-8220 mesylate

PKC

Positive

E9

N9-isopropyl-olomoucine

CDK

Negative

D10

d-Erythro-Sphingosine

PKC

Positive

E10

Olomoucine

CDK

Negative

D11

H-89 2HCl

PKA,

Negative

E11

Iso-olomoucine

Negative control for olomoucine

Negative

D12

H-8

PKA, PKG

Negative

E12

Roscovitine

CDK

Negative

F1

5-Iodotubericidin

ERK2, CK1, CK2

Positive

G1

Erbstatin analog

EGFRK

Negative

F2

LFM-A13

BTK

Negative

G2

Quercetin 2H2O

PI 3-K

Negative

F3

SB-202190

p38 MAPK

Negative

G3

SU1498

Flk1

Negative

F4

PP2

Src family

Negative

G4

ZM 449829

JAK-3

Positive

F5

ZM 336372

cRAF

Negative

G5

BAY 11-7082

IKK pathway

Positive

F6

SU 4312

Flk1

Negative

G6

5,6-dichloro-1-β-d-ribofuranosylbenzimidazole

CK II

Negative

F7

AG-1296

PDGFRK

Negative

G7

2,2′,3,3′,4,4′-Hexahydroxy-1,1′-biphenyl-6,6′dimethanol dimethyl ether

PKC alpha, PKC gamma

Negative

F8

GW 5074

cRAF

Negative

G8

SP 600125

JNK

Negative

F9

Palmitoyl-d l-carnitine

PKC

Negative

G9

Indirubin

GSK-3beta, CDK5

Negative

F10

Rottlerin

PKC delta

Positive

G10

Indirubin-3′-monooxime

GSK-3beta

Positive

F11

Genistein

Tyrosine kinases

Negative

G11

Y-27632 2HCl

ROCK

Negative

F12

Daidzein

Negative control for genistein

Negative

G12

Kenpaullone

GSK-3beta

Negative

H2

Triciribine

Akt signaling

Negative

H6

Apigenin

CK-II

Negative

H3

BML-257

Akt

Negative

H7

BML-265

EGFRK

Negative

H4

SC-514

IKK2

Negative

H8

Rapamycin

mTOR

Negative

H5

BML-259

Cdk5/p25

Negative